Optimizing Post-prostatectomy Radiotherapy: a Multi-disciplinary Perspective is organized by American Society for Radiation Oncology (ASTRO).

Release Date: Dec 14, 2017
Expiration Date: Dec 13, 2020

The target audience for this medical event is radiation oncologists, radiation therapists, and radiation dosimetrists. This CME Conference has been approved for a maximum of 1.25 AMA PRA Category 1 Credits.

Course Description:
The joint ASTRO/AUA guideline for post-prostatectomy radiotherapy was published in 2013 and provides guidance when offering patients either adjuvant or salvage radiotherapy. While it was written to influence clinical management, multiple reports suggest that this has not occurred on a broad scale. Furthermore, new prospective data has added complexity to this clinical situation. Today, there are even more questions that regard the optimal timing of radiotherapy, treatment field design, and when to offer hormonal therapy. More contemporary issues regarding the availability of genomic signatures, and questions regarding the potential benefit of adjuvant chemotherapy. A contemporary update can, therefore, help update attendees who may be unfamiliar with many of the nuances introduced by these developments. A pair of academic radiation oncologists and a leading urologic oncologist will comprise the educational panel.

Learning Objectives:
After this session, attendees should be able to:
• Understand the quality of evidence that supports post-prostatectomy radiotherapy, hormonal therapy and chemotherapy.
• Become familiar with the role of genomic signatures to stratify patients for adjuvant therapies following prostatectomy.

Additional details will be posted as soon as they are available.